Institutional Biosafety Committee (IBC)

An IBC is required for institutions receiving funding from the National Institutes of Health (NIH) for research involving recombinant or synthetic nucleic acid molecules. 

If your research involves the use of recombinant or synthetic nucleic acid molecules as described by the NIH Guidelines, human blood/tissue, pathogens, or potentially pathogenic material, you must register your project with the IBC. The IBC will review your submission and advise you of its findings.

The IBC meets monthly, usually on the first Friday of every month. The submission deadline for inclusion in a meeting is two weeks before the meeting. Please see the IBC Calendar for the exact dates. 

More information on IBC procedures can be found in the IBC Charter.

Key IBC Personnel

Vice Chair

Dr. Alan Schmaljohn

Acting Biosafety Officer

Matthew Fischer


Acting Assistant Biosafety Officer

John O’Neill


Related Links